EMA panel recommends extending use of AbbVie's Skyrizi drug to treat Crohn's disease

vzphotos

• The European Union drug regulator's human medicines committee has recommended extending the indication for AbbVie's (NYSE:ABBV) psoriasis and arthritis drug Skyrizi, according to the highlights of their latest meeting released on Friday.
• The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended the use of Skyrizi as a treatment for adults with moderate to severe Crohn's disease.
• Crohn's disease is a type of inflammatory bowel disease that causes swelling of the tissues in the digestive tract.
• Skyrizi was already approved in the European Union for the treatment of adults with moderate to severe plaque psoriasis and active psoriatic arthritis.
• ABBV stock +1.1% to $144.02 in early trading.